C12N 2310/344
Position-specific modifications
Official title: Position-specific modifications, e.g. on every purine, at the 3'-end
C12N2310/344 (Position-specific modifications) appears on 414 US grants and 824 published applications in this corpus.
Search patents in C12N- Granted patents
- 414
- Published applications
- 824
- Assignees
- 260
- Inventors
- 1,177
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 3 |
| 2006 | 0 | 2 |
| 2007 | 0 | 4 |
| 2008 | 0 | 3 |
| 2009 | 0 | 7 |
| 2010 | 5 | 14 |
| 2011 | 3 | 11 |
| 2012 | 9 | 17 |
| 2013 | 16 | 35 |
| 2014 | 16 | 33 |
| 2015 | 28 | 41 |
| 2016 | 22 | 47 |
| 2017 | 31 | 41 |
| 2018 | 44 | 45 |
| 2019 | 29 | 43 |
| 2020 | 30 | 47 |
| 2021 | 24 | 59 |
| 2022 | 39 | 74 |
| 2023 | 28 | 83 |
| 2024 | 39 | 93 |
| 2025 | 33 | 77 |
| 2026 | 17 | 44 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method for optimized RIG-I ligands6 Oct 2026US 12,751,965 B2
- Modified guide RNAs15 Sep 2026US 12,735,698 B2Intellia Therapeutics, Inc.
- Methods and compositions for inhibition of CRISPR re-cleavage events16 Jun 2026US 12,655,422 B2Integrated Dna Technologies, Inc.
- Chemically modified guide RNAs for genome editing with Cas12b9 Jun 2026US 12,649,921 B2Verve Therapeutics, Inc.
- 5′-modified carbocyclic ribonucleotide derivatives and methods of use26 May 2026US 12,636,301 B2Sanegene Bio USA Inc.
- Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes10 Sep 2026US 2026/0265746 A1Alnylam Pharmaceuticals, Inc.
- Oligonucleotides for htt-1a modulation10 Sep 2026US 2026/0265747 A1University of Massachusetts
- Fah-modulating compositions and methods3 Sep 2026US 2026/0258424 A1Flagship Pioneering Innovations VI, LLC
- Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use Thereof27 Aug 2026US 2026/0248964 A1Intellia Therapeutics, Inc.
- Compositions and methods for epigenetic regulation of pcsk9 expression27 Aug 2026US 2026/0250646 A1Chroma Medicine, Inc.
Most cited
By later US patents
- Oligonucleotides with alternating segments of locked and non-locked nucleotides183US 7,687,617 B2Santaris Pharma A/S · 2010
- Methods and compositions involving miRNA and miRNA inhibitor molecules171US 9,506,061 B2Asuragen, Inc. · 2016
- Lipid formulations for nucleic acid delivery119US 8,283,333 B2Protiva Biotherapeutics, Inc. · 2012
- Nucleic acid ligands of tissue target118US 6,127,119 ANeXstar Pharmaceuticals, Inc. · 2000
- Extended dicer substrate agents and methods for the specific inhibition of gene expression113US 8,513,207 B2Dicerna Pharmaceuticals, Inc. · 2013